<DOC>
	<DOCNO>NCT00453375</DOCNO>
	<brief_summary>The purpose study determine safety BHT-3021 injection give weekly 12 week evaluate effect BHT-3021 antibody immune ( T cell ) responses autoantigens ( e.g . insulin ) . Changes pancreatic beta cell function , insulin requirement blood glucose level also evaluate .</brief_summary>
	<brief_title>Phase 1 Study BHT-3021 Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Type 1 diabetes result attack body 's immune system insulin produce cell pancreas . Around 80 % diagnosed patient detectable antibody islet cell self-proteins include , insulin IA-2 glutamic acid decarboxylase . The drug , BHT-3021 study agent stop autoimmune damage could offer patient benefit . Study Description : A Randomized , Blinded , Placebo Controlled , Safety Pharmacodynamic Study BHT-3021 Open Label Cross-Over Subjects Type I Diabetes Mellitus enroll 72 subject trial . Subjects randomize BHT-3021 BHT-placebo 2:1 ratio . The duration study approximately 25 37 month depend treatment assignment : 4 week Screening Period ; 12 month Blinded Treatment Evaluation Period ; 12 month Cross-over Treatment Evaluation Period ( BHT-placebo subject ) ; 12 month Long Term Follow-Up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<criteria>Inclusion Criteria Diagnosis Type 1a Diabetes Mellitus base ADA Criteria ≤5 year since T1D diagnose ≥ 18 year age ≤ 40 year age time diagnosis Type 1a diabetes Presence antibody least one follow antigen : insulin , GAD65 , IA2 Detectable fast Cpeptide level Cpeptide increase screen mixed meal tolerance test minimal stimulate value ≥ 0.2 pmol/mL Presence antibody least one follow antigen : insulin , GAD65 , IA2 . If insulin antibody positive , determination must within 2 week insulin initiation BMI &gt; 30 kg/m2 Unstable blood sugar control define one episode severe hypoglycemia ( define hypoglycemia require assistance another person ) within last 30 day Current use inhalable insulin Previous immunotherapy T1D Administration experimental agent T1D time use experimental device T1D within 30 day prior screen , unless approve medical monitor History organ transplant , include islet cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Diabetic</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>autoimmune disease</keyword>
</DOC>